To: Board of Supervisors
From: Anna Roth, Health Services Director
Report Title: Purchase Order with Qiagen, LLC
☒Recommendation of the County Administrator ☐ Recommendation of Board Committee
RECOMMENDATIONS:
APPROVE and AUTHORIZE the Purchasing Agent, or designee, to execute on behalf of the Health Services Director, a purchase order with Qiagen, LLC in an amount not to exceed $800,000, and Master Purchasing Agreement, for the purchase of medical supplies including QuantiFERON -Tuberculosis (TB) and AmniSure products for the clinical laboratory at the Contra Costa Regional Medical Center (CCRMC), for the period from June 1, 2024 through May 31, 2027.
FISCAL IMPACT:
Approval of this action will result in expenditures of up to $800,000 over a three-year period and will be funded by Hospital Enterprise Fund I revenues.
BACKGROUND:
The CCRMC Clinical Laboratory Department (laboratory) has utilized Qiagen, LLC for reagents and supplies for QuantiFERON Tuberculosis (TB) and AmniSure testing.
TB testing is conducted with the Liaison XL Analyzer in the laboratory and reagents are only supplied by two vendors: Qiagen and the manufacturer of the analyzer. Utilizing products from any other vendor will void the warranty of the analyzer, which would negatively impact patient care should the analyzer need service. The AmniSure testing kits, supplied by Qiagen, detect the rupture of fetal membranes. These test kits allow for rapid, non-instrumented, qualitative immunochromatographic tests for the in-vitro detection of amniotic fluid in pregnant women. The timely identification and diagnosis of both fetal membrane ruptures and Tuberculosis is imperative and can significantly impact patient care and safety.
On April 18, 2023 the Board of Supervisors approved item C.63 to execute an amendment to purchase order #24587 with Qiagen, LLC to increase to a new payment limit of $790,000 to procure medical supplies including QuantiFERON products as needed for the Clinical Laboratory at Contra Costa Regional Medical Center (CCRMC), and extend the term through December 31, 2023.
On July 9, 2024 the Board of Supervisors approved item C.25 to authorize payment in the amount of $234,887 to Qiagen, LLC for QuantiFERON tubes during the period from January 1, 2024, through April 30, 2024.
On July 30, 2024 the Purchasing Agent approved the continued use of Qiagen, LLC.
Due to delays with the vendor processing the renewal request, the agreement was not completed until June 2024 and the agreement start date was pushed one month, from May 1 to June 1, 2024.
CONSEQUENCE OF NEGATIVE ACTION:
If this action is not approved, then the CCRMC Clinical Laboratory Department will not have access to this contractor’s specific patient testing supplies and reagents, thus impacting patient safety and health.